The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.

The Herpevac Trial for Women revealed that three dose HSV-2 gD vaccine was 58% protective against culture-positive HSV-1 genital disease, but it was not protective against HSV-2 infection or disease. To determine whether vaccine-induced immune responses had selected for a particular gD sequence in s...

Full description

Bibliographic Details
Main Authors: Miguel A Minaya, Maria Korom, Hong Wang, Robert B Belshe, Lynda A Morrison
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5407825?pdf=render